Innate Pharma Cash Flow Statement Analysis

Operating, investing, and financing activities in millions EUR

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Innate Pharma S.A. (IPHA) - Annual data in millions EUR
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-49.47-7.57-58.10-52.81-63.98-20.763.05
Depreciation & Amortization1.995.0945.414.6056.8016.537.40
Stock Based Compensation3.944.264.252.622.480.000.00
Change in Working Capital39.16-32.09-12.50-29.52-49.2040.25-47.10
Change in Accounts Receivable51.81-13.670.000.00-22.920.000.00
Change in Accounts Payable-1.01-3.89-7.66-0.95-6.530.000.00
Change in Other Working Capital-4.11-10.540.13-9.8925.380.000.00
Other Operating Activities-1.21-0.130.130.450.460.52-1.19
Net Cash from Operating Activities-6.90-32.56-19.16-58.46-51.7734.92-32.53
Investing Activities
Capital Expenditures-0.39-0.35-1.121.33-0.90-1.27-0.85
Purchases of Investments9.5922.773.000.00-3.000.000.00
Sales/Maturities of Investments9.59-2.003.000.41-3.002.0024.22
Other Investing Activities0.000.060.000.41-0.06-0.010.02
Net Cash from Investing Activities9.2020.631.88-0.92-13.37-62.1224.28
Financing Activities
Debt Repayment-8.94-2.36-2.03-2.07-2.25-1.98-1.34
Common Stock Issued2.930.400.200.500.0066.0162.56
Other Financing Activities2.930.000.00-0.310.000.000.00
Net Cash from Financing Activities-6.01-1.97-1.8326.82-1.1877.7761.22
Summary
Effect of Forex Changes on Cash-0.510.27-0.43-0.480.220.01-0.03
Net Change in Cash-4.21-13.62-19.10-33.04-66.3150.5752.97
Cash at Beginning of Period70.6184.23103.76136.79202.89152.3199.37
Cash at End of Period66.4070.6184.23-29.52136.79202.89152.31
Free Cash Flow-7.29-32.91-20.28-58.46-63.05-30.48-33.96
Supplemental Disclosures
Interest Paid0.000.000.000.310.340.000.00